These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies. Laine L; Katz PO; Johnson DA; Ibegbu I; Goldstein MJ; Chou C; Rossiter G; Lu Y Aliment Pharmacol Ther; 2011 Jan; 33(2):203-12. PubMed ID: 21114792 [TBL] [Abstract][Full Text] [Related]
103. Effects of 6-12 months of esomeprazole treatment on the gastric mucosa. Genta RM; Rindi G; Fiocca R; Magner DJ; D'Amico D; Levine DS Am J Gastroenterol; 2003 Jun; 98(6):1257-65. PubMed ID: 12818266 [TBL] [Abstract][Full Text] [Related]
104. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. Hassall E; Israel D; Shepherd R; Radke M; Dalväg A; Sköld B; Junghard O; Lundborg P J Pediatr; 2000 Dec; 137(6):800-7. PubMed ID: 11113836 [TBL] [Abstract][Full Text] [Related]
105. Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. Kiljander TO; Harding SM; Field SK; Stein MR; Nelson HS; Ekelund J; Illueca M; Beckman O; Sostek MB Am J Respir Crit Care Med; 2006 May; 173(10):1091-7. PubMed ID: 16357331 [TBL] [Abstract][Full Text] [Related]
117. A randomised prospective study comparing the effectiveness of esomeprazole treatment strategies in clinical practice for 6 months in the management of patients with symptoms of gastroesophageal reflux disease. Norman Hansen A; Bergheim R; Fagertun H; Lund H; Moum B Int J Clin Pract; 2005 Jun; 59(6):665-71. PubMed ID: 15924594 [TBL] [Abstract][Full Text] [Related]
118. Symptom-relieving effect of esomeprazole 40 mg daily in patients with heartburn. Johnsson F; Hatlebakk JG; Klintenberg AC; Román J Scand J Gastroenterol; 2003 Apr; 38(4):347-53. PubMed ID: 12739705 [TBL] [Abstract][Full Text] [Related]
119. Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial. Scheiman JM; Herlitz J; Veldhuyzen van Zanten SJ; Lanas A; Agewall S; Nauclér EC; Svedberg LE; Nagy P J Cardiovasc Pharmacol; 2013 Mar; 61(3):250-7. PubMed ID: 23188121 [TBL] [Abstract][Full Text] [Related]
120. Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. Li J; Zhao J; Hamer-Maansson JE; Andersson T; Fulmer R; Illueca M; Lundborg P Clin Ther; 2006 Mar; 28(3):419-27. PubMed ID: 16750456 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]